Data safety and drug safety in Germany: a closing gap?
Identifieur interne : 000A22 ( Main/Exploration ); précédent : 000A21; suivant : 000A23Data safety and drug safety in Germany: a closing gap?
Auteurs : Wolfgang Rathmann [Allemagne]Source :
- Pharmacoepidemiology and Drug Safety [ 1053-8569 ] ; 2001-12.
English descriptors
- KwdEn :
Abstract
Pharmacoepidemiology and drug utilization research are more and more involved in a fundamental conflict with data privacy regulations in Germany. In an attempt to close this gap, a working group of German data protection commissioners and representatives from epidemiologic research societies published guidelines on epidemiology and data protection, which are briefly reviewed. There are several data sources for drug utilization research and pharmacoepidemiology in Germany (national health surveys, routine data from hospitals, general practitioners, or statutory health insurance companies) allowing descriptive and analytic epidemiologic studies. Furthermore, since 1980 a random sample of all prescriptions of patients from statutory health insurances (GKV‐Arzneimittelindex) is analysed to produce an annual report on prescription drug use. More intensive use of health insurance data for evaluation of medical care including drug prescriptions is in discussion. The MediPlus (IMS HEALTH) database on 400 general and internal medicine practices provides an example to close the gap between the current demand for drug safety studies and data privacy issues. Finally, large provider systems with enormous data storage and data flow are emerging. Therefore, a further development of policies to guarantee ethically correct use of personally identifiable health data in the changing health care environment is urgently required. Copyright © 2001 John Wiley & Sons, Ltd.
Url:
DOI: 10.1002/pds.637
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Data safety and drug safety in Germany: a closing gap?</title><author><name sortKey="Rathmann, Wolfgang" sort="Rathmann, Wolfgang" uniqKey="Rathmann W" first="Wolfgang" last="Rathmann">Wolfgang Rathmann</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:058A2577D7220E0166C54B978AB3FBC8A625D8D1</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/pds.637</idno><idno type="url">https://api.istex.fr/document/058A2577D7220E0166C54B978AB3FBC8A625D8D1/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000804</idno><idno type="wicri:Area/Main/Curation">000799</idno><idno type="wicri:Area/Main/Exploration">000A22</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Exploration">000A22</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Data safety and drug safety in Germany: a closing gap?</title><author><name sortKey="Rathmann, Wolfgang" sort="Rathmann, Wolfgang" uniqKey="Rathmann W" first="Wolfgang" last="Rathmann">Wolfgang Rathmann</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Diabetes Research Institute at Heinrich Heine University, Department Biometrics and Epidemiology, Düsseldorf</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Düsseldorf</region><settlement type="city">Düsseldorf</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Pharmacoepidemiology and Drug Safety</title><title level="j" type="abbrev">Pharmacoepidem. Drug Safe.</title><idno type="ISSN">1053-8569</idno><idno type="eISSN">1099-1557</idno><imprint><publisher>John Wiley & Sons, Ltd.</publisher><pubPlace>Chichester, UK</pubPlace><date type="published" when="2001-12">2001-12</date><biblScope unit="volume">10</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="625">625</biblScope><biblScope unit="page" to="630">630</biblScope></imprint><idno type="ISSN">1053-8569</idno></series><idno type="istex">058A2577D7220E0166C54B978AB3FBC8A625D8D1</idno><idno type="DOI">10.1002/pds.637</idno><idno type="ArticleID">PDS637</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1053-8569</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>data privacy</term><term>database</term><term>drug safety</term><term>pharmacoepidemiology</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pharmacoepidemiology and drug utilization research are more and more involved in a fundamental conflict with data privacy regulations in Germany. In an attempt to close this gap, a working group of German data protection commissioners and representatives from epidemiologic research societies published guidelines on epidemiology and data protection, which are briefly reviewed. There are several data sources for drug utilization research and pharmacoepidemiology in Germany (national health surveys, routine data from hospitals, general practitioners, or statutory health insurance companies) allowing descriptive and analytic epidemiologic studies. Furthermore, since 1980 a random sample of all prescriptions of patients from statutory health insurances (GKV‐Arzneimittelindex) is analysed to produce an annual report on prescription drug use. More intensive use of health insurance data for evaluation of medical care including drug prescriptions is in discussion. The MediPlus (IMS HEALTH) database on 400 general and internal medicine practices provides an example to close the gap between the current demand for drug safety studies and data privacy issues. Finally, large provider systems with enormous data storage and data flow are emerging. Therefore, a further development of policies to guarantee ethically correct use of personally identifiable health data in the changing health care environment is urgently required. Copyright © 2001 John Wiley & Sons, Ltd.</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>District de Düsseldorf</li><li>Rhénanie-du-Nord-Westphalie</li></region><settlement><li>Düsseldorf</li></settlement></list><tree><country name="Allemagne"><region name="Rhénanie-du-Nord-Westphalie"><name sortKey="Rathmann, Wolfgang" sort="Rathmann, Wolfgang" uniqKey="Rathmann W" first="Wolfgang" last="Rathmann">Wolfgang Rathmann</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/SchutzV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A22 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A22 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= SchutzV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:058A2577D7220E0166C54B978AB3FBC8A625D8D1
|texte= Data safety and drug safety in Germany: a closing gap?
}}
| This area was generated with Dilib version V0.6.38. |  |